EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Open Access · CC BY-NC 4.0

Population Pharmacokinetics and Exposure‐Response Model‐Based Bayesian Extrapolation of FVC ‐Based Efficacy Endpoints From Adults to Pediatric Patients Receiving Nintedanib

Sonja Hartmann iD, Anna Chan Kwong iD, Jakob Ribbing iD, Martina Gahlemann, Julia Korell iD

CPT: Pharmacometrics & Systems Pharmacology · 2026

DOI: 10.1002/psp4.70135 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift CPT: Pharmacometrics & Systems Pharmacology, 2026. Verfasst von Sonja Hartmann und 4 weiteren Autor:innen. Beteiligte Einrichtung: Translational Medicine and Clinical Pharmacology, Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut, USA. Hauptthemen laut MEDLINE: Indoles, Models, Biological, Idiopathic Pulmonary Fibrosis, Lung Diseases, Interstitial. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Nintedanib reduces the rate of decline in forced vital capacity (FVC) in adult patients with idiopathic pulmonary fibrosis (IPF), chronic progressive‐fibrosing interstitial lung diseases (ILDs) and systemic sclerosis‐associated ILD (SSc‐ILD). A pediatric Phase 3 trial (InPedILD) has been conducted in children 6–17 years, and partial extrapolation from adults to pediatrics was performed to support dose selection and benefit–risk assessment in pediatric patients with progressive‐fibrosing ILDs. Previously developed population pharmacokinetic (popPK) and efficacy exposure‐response (ER) meta‐models across all non‐oncologic pulmonary indications of nintedanib in adults were used as a basis for partial extrapolation to pediatric patients. Data from InPedILD and its open‐label extension trial (InPedILD‐ON) were incorporated and a Bayesian approach was utilized to extrapolate PK and FVC‐based efficacy endpoints. PK of nintedanib was adequately described using a similar structure as the adult popPK model. The weight‐based dosing scheme applied in InPedILD resulted in exposures similar to those in adult patients receiving the approved dose of nintedanib 150 mg twice daily. The ER models for FVC %predicted and FVC Z ‐score were similar to those developed in adults. Compared to adults, pediatric patients showed a slower estimated rate of decline for both endpoints. The estimated EC50 and Emax values in children and adolescents were comparable to those in adults. Partial extrapolation from adult to pediatric patients showed that the pre‐defined pediatric dosing regimen resulted in similar nintedanib exposures compared to the efficacious exposures in adults. ER models suggested a similar beneficial treatment effect of nintedanib on FVC in children and adults.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

IndolesModels, BiologicalIdiopathic Pulmonary FibrosisLung Diseases, InterstitialHumansChildBayes TheoremAdolescentAdultVital CapacityMaleFemaleMiddle AgedDose-Response Relationship, DrugScleroderma, SystemicTreatment Outcome

Stichwörter der Autor:innen

Bayesian extrapolationinterstitial lung diseasesnintedanibnonlinear mixed effects modelingpediatric drug development

Substanzen

nintedanibIndoles

Autor:innen und Institutionen

  • Translational Medicine and Clinical Pharmacology, Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut, USA.
  • Pharmetheus AB, Uppsala, Sweden.
  • Boehringer Ingelheim (Schweiz) GmbH, Basel, Switzerland.

ORCID-Profile: Sonja Hartmann, Anna Chan Kwong, Jakob Ribbing, Julia Korell

Zitieren

APA

Hartmann, S., Chan Kwong, A., Ribbing, J., Gahlemann, M., & Korell, J. (2026). Population Pharmacokinetics and Exposure‐Response Model‐Based Bayesian Extrapolation of FVC ‐Based Efficacy Endpoints From Adults to Pediatric Patients Receiving Nintedanib. CPT: Pharmacometrics & Systems Pharmacology. https://doi.org/10.1002/psp4.70135

Vancouver

Hartmann S, Chan Kwong A, Ribbing J, Gahlemann M, Korell J. Population Pharmacokinetics and Exposure‐Response Model‐Based Bayesian Extrapolation of FVC ‐Based Efficacy Endpoints From Adults to Pediatric Patients Receiving Nintedanib. CPT: Pharmacometrics & Systems Pharmacology. 2026. doi:10.1002/psp4.70135

BibTeX
@article{Hartmann2026,
  author = {Hartmann, Sonja and Chan Kwong, Anna and Ribbing, Jakob and Gahlemann, Martina and Korell, Julia},
  title = {Population Pharmacokinetics and Exposure‐Response Model‐Based Bayesian Extrapolation of FVC ‐Based Efficacy Endpoints From Adults to Pediatric Patients Receiving Nintedanib},
  journal = {CPT: Pharmacometrics & Systems Pharmacology},
  year = {2026},
  doi = {10.1002/psp4.70135}
}
Kostenlos starten →